Genelux Corporation Common Stock
Yahoo Finance • last year
Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer
- Pivotal Phase 3 Study of Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer Initiated in September 2022 - - Phase 2 Trial of Olvi-Vec- Demonstrated Clinical Reversal of Platinum Resistance and Refractoriness and Met Primary Endpoi... Full story
Yahoo Finance • last year
Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates
- Expanded executive team as Lourie Zak appointed Chief Financial Officer - - Extended clinical focus on systemic administration in small cell lung cancer - - $29.9 million in cash and equivalents - WESTLAKE VILLAGE, Calif., Nov. 14, 2... Full story
Yahoo Finance • last year
Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that on September 11, 2023, the Company’s Board of Directors (the “Board”) gr... Full story
Yahoo Finance • last year
Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
WESTLAKE VILLAGE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, Chairman and CEO, will present a corporate o... Full story
Yahoo Finance • last year
Genelux Corporation Announces New Chief Financial Officer
WESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Lourie S. Zak will join the company as Chief Financial Officer, effective... Full story
Yahoo Finance • last year
Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates
- Inclusion into the broad-market Russell 3000® Index and small-cap Russell 2000® Index - - Publication of VIRO-15 Phase 2 data in JAMA Oncology - - $51 Million raised after closing of two private placements in Q2, totaling $65 million r... Full story
Yahoo Finance • 2 years ago
Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Immunology
Phase 1 trial conducted at Memorial Sloan Kettering Cancer Center, New York, investigated the safety, feasibility and immune activating effects of Olvi-Vec by intrapleural administration. Documented Olvi-Vec infection of tumor cells, which... Full story
Yahoo Finance • 2 years ago
Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics™, LLC
- V2ACT Therapeutics™, LLC is a joint venture between Genelux Corporation and TVAX Biomedical, Inc. - V2ACT Immunotherapy is a proprietary immuno-oncology modality composed of Olvi-Vec (oncolytic viral immunotherapy) and TVAX Immunotherap... Full story
Yahoo Finance • 2 years ago
Genelux Corporation Set to Join the Russell 3000® and Russell 2000® Indexes Effective June 26, 2023
WESTLAKE VILLAGE, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that it will be added to the broad-market Russell 3000® Index and small-cap Ru... Full story
Yahoo Finance • 2 years ago
Genelux Corporation Announces $18 Million Private Placement
WESTLAKE VILLAGE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement for 900,000 shares of the Company's common stock at a purc... Full story
Yahoo Finance • 2 years ago
Genelux Corporation Announces $33 Million Private Placement
WESTLAKE VILLAGE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of 1,665,247 shares of the Company's common stock at a pric... Full story
Yahoo Finance • 2 years ago
Genelux Corporation to Ring Nasdaq Opening Bell on March 29, 2023
WESTLAKE VILLAGE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) (“Genelux” or “the Company”), a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic v... Full story
